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ABSTRACT: High-throughput screening platforms for the
identiﬁcation of bioactive compounds in mixtures have
become important tools in the drug discovery process.
Miniaturization of such screening systems may overcome
problems associated with small sample volumes and enhance
throughput and sensitivity. Here we present a new screening
platform, coined picofractionation analytics, which encom-
passes microarray bioassays and mass spectrometry (MS) of
components from minute amounts of samples after their nano
liquid chromatographic (nanoLC) separation. Herein,
nanoLC was coupled to a low-volume liquid dispenser
equipped with pressure-fed solenoid valves, enabling 50-nL
volumes of column eﬄuent (300 nL/min) to be discretely deposited on a glass slide. The resulting fractions were dried and
subsequently bioassayed by sequential printing of nL-volumes of reagents on top of the spots. Unwanted evaporation of
bioassay liquids was circumvented by employing mineral oil droplets. A ﬂuorescence microscope was used for assay readout in
kinetic mode. Bioassay data were correlated to MS data obtained using the same nanoLC conditions in order to assign
bioactives. The platform provides the possibility of freely choosing a wide diversity of bioassay formats, including those
requiring long incubation times. The new method was compared to a standard bioassay approach, and its applicability was
demonstrated by screening plasmin inhibitors and ﬁbrinolytic bioactives from mixtures of standards and snake venoms,
revealing active peptides and coagulopathic proteases.
Current approaches used for analyzing complex mixturesfor bioactivity properties involve the use of screening
platforms that commonly combine several analytical techni-
ques.1−3 The so-called nanofractionation approach encom-
passes liquid chromatographic (LC) separation, using conven-
tional-bore columns, online coupled to UV absorbance and
mass spectrometric (MS) detection, as well as to a bioassay via
continuous collection of microliter fractions of the column
eﬄuent.1 Fractions of 3- to 10-s are collected on microtiter
well plates and subsequently centrifuge freeze-dried and
exposed to a bioassay of choice. The overall bioassay readout
is then constructed into a bioactivity chromatogram and
correlated to the parallel obtained UV-absorbance and MS data
with the objective to identify (unknown) bioactive com-
pounds. This technology has been applied successfully to a
wide range of complex mixtures, including snake venoms,4−6
plant extracts,7 environmental samples,8,9 and metabolic
mixtures of new chemical entities (NCEs).10
Natural samples such as animal venoms or bioﬂuids from
small animals may be precious sources of new drugs. However,
these samples are often only available in very small amounts
and are therefore typically not suitable for most established
screening platforms. Microﬂuidic high-resolution screening
(HRS) platforms1 employing online homogeneous bioassays
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have shown potential to tackle this problem.11,12 However,
these systems allow only short incubation times and require
relatively high concentrations of a soluble target protein (e.g.,
receptor or enzyme) to attain satisfactory performance. An
alternative to online microﬂuidic bioassaying could be the
coupling of microarray bioassays, which can accommodate
hundreds to thousands of minute-volume bioassay reactions, to
nano liquid chromatography (nanoLC), which employs nL/
min range ﬂow rates and small sample injection volumes (nL
to low μL). Small molecular microarrays (SMMs) have been
successfully implemented in drug discovery processes,13−15
such as for drug−drug interaction screening of cytochrome
P450 enzymes16−18 and drug cytotoxicity evaluation,19,20 but
have also found application in the identiﬁcation of pesticides in
food21 and environmental samples22 and of bioweapon
toxins.23 However, these microarray platforms are only suited
for screening pure compound libraries or single-analyte
samples, limiting their usefulness to analyze complex mixtures
of bioactive compounds, such as venoms and natural extracts,
as they would require preseparation.
Oﬀ-line chemical analysis of mixtures of components after
nanoLC24 has been achieved via fractionation of nanoLC
eﬄuent using various deposition approaches.25−29 Pereira et
al.28 and Küster et al.26,27 used a microﬂuidics T-junction for
contact deposition generating droplets by shear force using
perﬂuorodecalin and subsequent spotting onto plates for
MALDI-MS. Küster et al.26 managed to deposit liquid droplets
of ∼2.5 nL. Noncontact deposition of low-nL volume droplets
requires application of some sort of force to dislodge droplets
from a dispensing tip. Young and Li29 applied a pulsed voltage
to a solenoid coil to deposit eﬄuent droplets from a connected
fused-silica capillary onto MALDI-plates in a noncontact
fashion. This method was shown to be optimal for droplet sizes
above 100 nL, but by decreasing the distance between the
surface of the collecting plate and the capillary tip, spot
volumes down to 20 nL could be achieved.
In the present study, we introduce a new fractionation
platform for proﬁling bioactive components in small volumes
of complex mixtures after separation by nanoLC. This
“picofractionation” system analyzes nL to low-μL sample
volumes and deposits 10-s fractions (50 nL each) of nanoLC
eﬄuent onto a coated glass slide. Our study for the ﬁrst time
demonstrates proof of concept analytics enabling nanoLC
separations with nanoliter regime fraction collection followed
by integrated postcolumn bioassaying. For this purpose, a
nanoliter-volume liquid dispenser was used, providing
contactless droplet array printing of the column eﬄuent. The
bioactivity of the fractionated samples was assessed by applying
a ﬂuorescence-based bioassay using a spot-on-spot approach.
Microarray bioassay readout was performed kinetically using a
modiﬁed ﬂuorescence microscope. The resulting data were
converted to microarray bioactivity chromatograms (MBCs),
in which each point represents a slope of each bioassay
reaction present on a glass slide. The MBCs were correlated
with nanoLC-UV and -MS data for (structural) assignment of
bioactive compounds. We evaluated the described picofractio-
nation platform by employing a plasmin bioassay for the
proﬁling of four snake venoms in order to detect the presence
of plasmin inhibitors (antiﬁbrinolytic agents) and proteases
with ﬁbrinolytic-like activities. The term “picofractionation”
was chosen to continue the already existing nomenclature for
fractionation platforms. Starting with microfractionation
systems, the collected fractions often were found to be in the
milliliter range.30−33 We found that this naming system was
used already in publications dated as early as 1951.30
Successively, platforms working in the microliter range were
called nanofractionation.34−36 Therefore, in this study we
called the presented nanoliter range fractionation platform
picofractionation.
■ EXPERIMENTAL SECTION
Chemicals and Snake Venoms. All chemicals used were
purchased commercially, and the details can be found in
Supporting Information (SI) section S1.
Lyophilized snake venom samples from Bothrops asper
(Costa Rica), Deinagkistrodon acutus (captive bred of Chinese
origin), Trimeresurus trigonocephalus (Sri Lanka), and Trimer-
esurus purpureomaculatus (Thailand) were sourced from
historical venom samples stored in the Centre for Snakebite
Research & Interventions at the Liverpool School of Tropical
Medicine. For analysis, the venoms were diluted in Milli-Q
water from a stock solution (5 mg/mL in water) to a
concentration of 1 mg/mL. The venom samples were stored at
−80 °C until use.
Preparation of Glass Slides and Coating. To ensure a
hydrophobic surface, standard microscope glass slides (76 × 26
mm) with ground edges from Fisher Scientiﬁc (Lough-
borough, United Kingdom) were coated with 4 mL of a
mixture comprising 16 mL of methyltrimethoxysilane
(MTMOS), 6.4 mL of 5 mM HCl, and 16 mL of 25 mM
potassium phosphate buﬀer at pH 8 according to the protocol
of Lee et al.37 The slides were coated at least 4 days prior to
nanoLC spotting. Detailed information on the coating
procedure can be found in SI section S2.
NanoLC. NanoLC was performed with a Dionex Ultimate
3000 nanoLC system from Thermo Scientiﬁc equipped with
an autosampler, two binary high pressure gradient pumps, one
loading pump, and a variable wavelength UV absorbance
detector set to 214 nm. Samples (1 μL unless otherwise stated)
were ﬁrst loaded onto a trapping column (0.3 mm ID; 5 mm
length; packed with Acclaim PepMap 100 C18 from Thermo
Fisher; 5 μm pore size) for 6 min using a loading pump
delivering acetonitrile−water (2:98; v/v) with 0.1% TFA at a
ﬂow rate of 10 μL/min. After 6 min the trapping column was
switched in line with the analytical column (C18; 75 μm ID;
150 mm length; 2 μm pore size) through a 6-port switch valve.
All analyses were performed using a gradient elution with a
mobile phase comprised of solvent A (water−acetonitrile−
formic acid (98:2:0.1; v/v/v)) and solvent B (acetonitrile−
water−formic acid (98:2:0.1; v/v/v). Further information on
the nanoLC gradients can be found in SI section S3.
For sample analysis with MS detection, the nanoLC was
coupled to a Bruker TIMS-TOF instrument (Bremen,
Germany) using a CaptiveSpray source and a nanoBooster
(Bruker Daltonics) employing acetonitrile. The MS source
settings were as follows: capillary voltage, 1200 V; nanoBooster
gas pressure, 0.25 bar; temperature, 150 °C. The range of m/z
50−3000 was covered. For nanoLC-MS analysis the injection
volumes for D. acutus, T. trigonocephalus, and T. purpureoma-
culatus were 100 nL and for B. asper 500 nL. The
chromatographic methods (i.e., gradients) used to separate
the standard solution (a mixture of leupeptin diastereoisomers)
and the dissolved snake venoms were the same as used for the
postcolumn microarray bioassaying analyses.
Fractionation of nanoLC Eﬄuent. Collection of nano-
liter fractions of nanoLC eﬄuent was facilitated by the
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nanovolume liquid dispenser Preddator from Red&Whyte
Limited (London, UK) equipped with four (1−4) pressure fed
solenoid valves (The presentation of valves 1−4 can be found
in Figure S2). The nanoLC eﬄuent was led to the Preddator
by a ∼30 cm long fused-silica capillary (75 μm I.D. and 365
μm O.D.) which was connected to the 280-μm O.D. capillary
exiting the UV absorbance detector using a Teﬂon sleeve
connector (Thermo Scientiﬁc). The other end of the fused-
silica capillary was inserted into a ﬂuorinated ethylene
propylene (FEP) tubing sleeve (length 5.8 cm; O.D. 1/16
in.; I.D. 0.0155 in.) which was mounted in a custom-made
holder placed to the left side of the dispensing arm of the
Preddator that moves in XY directions (Figure 1A). A
schematic view of the platform is shown in Figure 1. The tip
of the capillary inserted into the FEP tubing sleeve was
protruding ∼5 mm outside the tubing sleeve and was placed
centrally below the opening of the most left positioned
solenoid valve (1) in the arm of the Preddator (Figure 1B).
Figure S3 presents a zoomed image of the interface between
nanoLC and the nanovolume liquid dispenser. Collection of
nanoliter eﬄuent fractions was possible by using solenoid valve
1 to dispense water droplets of 100 nL that hit and merge “in
ﬂight” with the eﬄuent droplets exiting the tip of the
connecting capillary, providing contact-free deposition of LC
eﬄuent fractions onto the receiving glass slide (Figure 1D−E).
Correct positioning of the capillary tip was essential in order to
achieve repeatable and microarray-bioassay-compatible collec-
tion of the nanoLC eﬄuent. To prevent “climbing” of the
droplet along the outside of the capillary by adhesion forces, its
tip was silylated with MTMOS coating solution (more detailed
information on the capillary preparation can be found in SI,
section S4). This treatment renders the tip more hydrophobic
and lasted for ∼3−4 weeks. The picofractionation process was
managed by the in-house developed software Ariadne v. 1.10,
enabling spotting of eﬄuent fractions ranging from 0.1 to 900
s. In this study, a fraction was spotted every 10 s.
Microarray Plasmin-Activity Assay with Fluorescence
Readout. The deposited nanoliter fractions were exposed to a
plasmin bioassay that was adapted from a previously developed
384 microtiter well-plate format as described by Zietek et al.38
Collected eﬄuent fractions dried within ∼5 min at ambient
atmosphere and were then covered with a 100-nL drop of
water dispensed by solenoid valve 3 of the Preddator (spot-on-
spot; Figure 1, Figure S2) at an overpressure of 200 mbar (i.e.,
atmospheric pressure +200 mbar). Next, 100 nL of a 200 ng/
mL plasmin solution dissolved in 0.1 M Tris-HCl buﬀer
enriched with 0.1% BSA (w/v) was spotted onto the water
droplets on the glass slides using solenoid nozzle 2 at an
overpressure of 200 mbar. Then, two droplets of mineral oil
(200 nL each) were dispensed 0.2 mm left and right,
respectively, of each spotted droplet of plasmin solution, in
order to prevent disintegration of the enzyme solution droplet.
The mineral oil was used to prevent evaporation of the
bioassay liquids and was dispensed using solenoid valve 4 at an
overpressure of 1650 mbar. Several other spotting sequences
were tested prior to reaching the here described optimal
procedure (see Figure S4). After depositing the mineral oil, the
spots were incubated for 30 min at RT under a polystyrene
black cover, without touching the surface of the glass slide.
Finally, the bioassay was initiated by dispensing 100 nL of the
ﬂuorogenic substrate H-D-Val-Leu-Lys-AMC (10 μM) onto
the incubation droplets, with solenoid valve 2 at an
overpressure of 200 mbar. The prepared microarray glass
Figure 1. Schematic representation of a picofractionation platform.
Under orange shading (right side of the ﬁgure) the main steps of the
picofractionation method are outlined: (1) a complex mixture is
injected; (2) mixture separation on nanoLC column; (3) the eluting
sample components are ﬁrst measured with an ultraviolet−visible
detector [UV−vis]; (4) split to picofractionation and MS; (5) eﬄuent
droplets are picofractionated (10-s fractions) and collected on a
coated glass slide (A: nanoLC eﬄuent is delivered by a glass capillary
that is inserted into a ﬂuorinated ethylene propylene (FEP) tubing
sleeve mounted to an arm of a low volume liquid dispenser; (B) the
glass capillary is protruding outside the sleeve tube and is positioned
directly below the nozzle of the solenoid valve; (C) solenoid valve
dispensing 100 nL of water; (D) water droplets ejected from the
solenoid valve hit and merge “in ﬂight” with the nanoLC eﬄuent
droplet (50 nL), dispensing them on a coated glass slide (E); (6)
evaporation of collected nanoLC eﬄuent droplets; (7) spotting of the
bioassay solutions; (8) bioactivity measurement with ﬂuorescence
microscope; (9) mass spectrometric (MS) measurement; (10)
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slide was then directly placed in a glass slide holder of a
Mar̈zhaüser Wetzlar XY stage (type SCAN IM 130 × 100;
Wetzlar, Germany) mounted on top of a Lumascope 620
(Etaluma, Carlsbad, CA, USA) inverted ﬂuorescence micro-
scope for ﬂuorescence readout and image acquisition (Figure
S5). For detection of the product of the enzymatic reaction (7-
amino-4-methylcoumarin (AMC)) an excitation ﬁlter of 370−
410 nm was used. In the Lumascope 620, ﬂuorescence
emission light was detected by a digital camera containing a
high sensitivity monochrome complementary metal oxide
semiconductor (CMOS) image sensor. An apochromatic
microscope objective with 4× magniﬁcation (numerical
aperture (NA), 0.13; working distance (WD), 17.2 mm, type
number MA1012) from Meiji Techno (San Jose, California,
USA) was used for the measurements. To automate image
acquisition of all microarray bioassay spots at ﬁxed time
intervals (i.e., kinetic measurements), the XY stage and the
ﬂuorescence microscope were controlled with the μManager
(version 1.4) open source software39 that allowed synchroniza-
tion of the hardware. Information on the image acquisition and
processing of the microarray data can be found in SI, section
S5.
Performance and Quality of the Plasmin Microarray
Bioassay. The performance of the microarray bioassay was
ﬁrst evaluated by determining IC50 values of the plasmin
inhibitors leupeptin and aprotinin. Details on this procedure
can be found in SI S6. The Z′-factor, a standardized statistical
tool described by Zhang et al.40 was used to determine the
assay quality (see SI S7).
■ RESULTS AND DISCUSSION
We present the development and validation of a so-called
picofractionation screening platform which combines nanoLC
of bioactive samples with microarray bioassaying employing a
ﬂuorescence microscope via contactless fractionation of the
nL/min column eﬄuent. Parallel nanoLC-MS analyses of the
same samples were performed for correlating bioactivity of
components to their accurate mass.
Fractionation of nanoLC Eﬄuent. To achieve non-
contact deposition of 50-nL fractions of nanoLC eﬄuent, a
fused-silica capillary connected to the nanoLC column was
positioned at an angle of 45° just underneath a solenoid valve
of a dispensing arm of a high-accuracy low-volume dispenser
(Figure S3). We chose a noncontact deposition because it
oﬀers a number of advantages over contact deposition, and
these include a better repeatability and reproducibility of the
deposited droplets, less chance of droplet contamination and
memory eﬀects, and no damage to the surface of the glass slide
and/or nanoLC capillary (such as scratching the surface or
crushing of the capillary). The latter is important in the case of
ﬂuorescence readouts as any damage to the surface of the glass
slide would cause artifacts contributing to light scattering and
increases in overall background signal which will aﬀect the
quality of the measurement. Finally, the noncontact spotting
mode omits the use of a Z-stage in the spotting movement
procedure and the hardware, which renders the system less
technically complicated. In addition, X,Y stage spotting
intrinsically is much faster since the Z-movement for every
droplet deposition is not needed. Positioning, and the angle of
the capillary with respect to the nozzle of the solenoid valve,
along with the shape of the capillary tip, were important
parameters to ensure reproducible and accurate deposition of
eﬄuent droplets on to the microarray glass slide. A capillary
with a blunt end and a hydrophobic tip (silylated with
MTMOS), prevented “climbing” of liquid along the outside of
the capillary and yielded optimal detaching of nanoLC eﬄuent
by the ejected water droplets. The distance between the
nanoLC eﬄuent capillary and the spotter nozzle was kept small
(∼2 mm), as was the distance between the capillary tip and the
glass slide surface (∼2 mm). These parameters provided
precise and consistent droplet deposition on the glass slide for
mobile phases containing up to 67% solvent B. Above this
percentage of solvent B, the position of the capillary had to be
adjusted ∼0.5 mm further away from the spotter nozzle
(decreasing the distance between the tip of the capillary and
the glass slide to less than 1.5 mm) in order to ensure
appropriate droplet deposition. As future technical advance-
ment of the methodology, automatic adjustment of the needle
will be incorporated into the system.
Microarray Bioassay Format. The bioactivity of individ-
ual compounds separated by nanoLC and deposited on the
glass slide has to be measured with a bioassay suitable for
microarray formats. Bioassaying in small volumes raises issues
associated with unwanted evaporation of bioassay solvents and
with redissolving of the dried fractions. To prevent water
evaporation during the microarray assay incubation, we
adapted the droplet-in-oil approach of Sun et al.41 In their
approach, mineral oil was spotted ﬁrst on a glass slide to
generate droplet arrays into which analytes and the bioassay
components were ejected for generation of bioassay-in-oil-
droplets. However, in our case, after column eﬄuent droplet
spotting, the LC solvent evaporates leaving dry spots.
Therefore, prior to spotting of the enzyme solution, a 100-
nL droplet of water was dispensed on top of the dried fraction,
in order to redissolve deposited components and thus to
facilitate their mixing with the enzyme. The water droplet was
partially evaporated (approximately 70% by visual assessment)
prior to spotting of the enzyme solution to avoid additional
dilution of the bioassay components. Then, mineral oil was
spotted to the plasmin solution, followed by 30 min incubation
at room temperature under a polystyrene cover. However,
spot-on-spot printing of the oil resulted in disintegration of the
previously spotted droplets of the plasmin solution. Therefore,
diﬀerent approaches of spotting mineral oil onto the bioassay
reaction mix were evaluated (see Figure S4 for details). We
found that spotting two oil droplets 0.2 mm adjacent (left and
right) to an enzyme droplet maintained the enzyme droplet’s
integrity, while the two oil droplets merged into one, covering
the enzyme droplet. The bioassay reaction was subsequently
initiated by spotting 100 nL of substrate solution through the
oil cover into the enzyme and sample component-containing
inner droplet. The mineral oil droplets were not removed from
the reaction droplets. They were kept throughout the bioassay
reactions as dome shaped cover shells to prevent the bioassay
mixtures from evaporating. Considering the highly nonpolar
nature of mineral oil, partitioning of the compounds relevant
to this research (i.e., peptides, protein and relatively polar small
molecules) is not an issue.
Figure 1. continued
bioactivity data and chemical data correlation. MBC = Microarray
Bioactivity Chromatogram generated by plotting bioassay activity
(slopes) over 18 measurements of individual droplets on y-axis and
fractionation time on x-axis; RT = retention time; MS = mass
spectrometry.
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Even when taking an enzyme solution that was prepared
freshly from a stock kept at −20 °C, a decrease of enzymatic
activity over time was observed when the solution was
dispensed (data not shown). This activity loss appeared to
be due to exposure to ambient temperature solution and
evaporation of the enzyme solution. Therefore, the enzyme
solution was kept on ice as long as possible prior to dispensing
and then dispensed quickly followed by coverage with mineral
oil. This was achieved by dispensing not more than 100
droplets with one portion of cold enzyme solution. For the
next 100 droplets, a new cold portion was used. Fast
dispensing of the enzyme and the oil was achieved by time-
optimizing the point-to-point movement of the liquid
dispenser using the control software.
The biochemical conditions and reagent concentrations of
the plasmin inhibition assay used in an earlier developed plate
reader format38 were transferred to and evaluated with the
microarray bioassay format. The microarray assay quality and
dynamic range were assessed by determining the Z′-factor,
which was 0.71, indicating an excellent bioassay according to
Zhang et al.40 (Figure 2). Comparable results were obtained
for the 384-well plate format, where the Z′-factor for the same
bioassay was determined to be 0.74.38 The good agreement in
the Z′-factors shows the straightforward transfer of a bioassay
initially developed for the 384-well plate format (operating at
50 μL well volume) to the microarray format that requires only
200 nL of the bioassay mixture (i.e., 250 times lower volume).
Although when considering the biological aspects only the two
methods are expected to provide similar results, the diﬀerence
lies in the technical diﬃculties. Performing a bioassay in for
example 50 μL volume in wells of a well plate with readout
using a standardized platereader is routine laboratory work. In
contrast, the technical diﬃculties of preparing and measuring
bioassays in 200 nL volumes are extremely high. Besides, all
preparation steps (i.e., spotting), measuring procedures (i.e.,
the in-house developed confocal microscope bioassay spot
reader), and data processing with automated spot recognition
and integrated kinetic bioassay development monitoring per
spot are complex and far from trivial.
In order to evaluate whether the microarray bioassay can
accurately determine inhibitory properties of bioactives, IC50
values of two potent plasmin inhibitors, leupeptin and
aprotinin, were determined and compared with IC50 values
obtained using the standard 384-well plate reader bioassay.38
Determination of IC50 values was performed with the
microarray bioassay on dried inhibitor spots that were spotted
on a MTMOS coated glass slide. Leupeptin and aprotinin were
dispensed at ten diﬀerent concentrations ranging from 0 to 400
μM and from 0 to 30 μM, respectively. Figure S6 shows the
IC50 curve of leupeptin obtained with the microarray bioassay.
The IC50 for leupeptin was found to be 4.7 μM (SD, 2.7 μM),
which was approximately two times lower than the IC50
obtained using the 384-well plate reader format (8.9 μM; SD,
3.1 μM). For aprotinin an IC50 value of 51 nM (SD, 27 nM)
was determined with the microarray bioassay, whereas the
IC50 value was 35 nM (SD, 14) with the plate reader assay
(Figure S6). Choo et al.42 reported an IC50 of 21.7 nM for
aprotinin against plasmin. Hence, although we used diﬀerent
conditions for our plasmin bioassaywe used a diﬀerent
enzyme concentration and a ﬂuorogenic instead of a
chromogenic substrate as in the case of Choo et al.the
inhibitory potency of aprotinin toward plasmin found in our
study agreed well with the value of Choo et al.
NanoLC-Microarray Bioassaying of Plasmin Inhib-
itors. In order to evaluate the performance of the
picofractionation platform, in terms of repeatability and
sensitivity, various concentrations of a mixture of leupeptin
and aprotinin were analyzed by nanoLC and the column
eﬄuent was fractionated on MTMOS-coated glass slides.
Figure 3 shows representative resulting microarray bioactivity
chromatograms (MBCs) of leupeptin injected at concen-
trations ranging from 10 to 200 μM. The highest concentration
injected induced full inhibition of plasmin, which is depicted in
Figure 3 as a negative peak in the upper superimposed
chromatogram. A gradually lower percentage of full inhibition
was observed upon injection of lower leupeptin concentrations,
as reﬂected by decreasing heights of the negative peaks. A
Figure 2. Bioassay evaluation with Z′-factor. Positive control
(leupeptin at 200 μM; n = 100) and negative control (mobile
phase A; n = 100). SD: standard deviation.
Figure 3. Superimposed microarray bioactivity chromatograms
(MBCs) resulting from microarray bioassays of fractionated leupeptin
(left) and aprotinin (right) injected at diﬀerent concentrations to
nanoLC. The MBCs are correlated with nanoLC-UV traces (bottom)
obtained from measurement of leupeptin and aprotinin at 25 μM and
30 μM, respectively. For these analyses a short chromatographic
gradient of 35 min was used.
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concentration of 10 μM appeared to be the bioassay detection
limit. Although comparable, in our previous study in which a
nanofractionation system was used, the detection limit for
leupeptin was 6.3 μM.38 It has to be noted that miniaturized
bioassays do not lead to increased sensitivity as in the case of
nanoLC-MS analysis of especially peptide mixtures (for
proteomics analyses for example). Bioassay sensitivity depends
on the bioassay and the detection system used for readout.
Considering that in our current study a prototype custom-built
new analytical device was used, a slightly lower ﬂuorescence
signal and thus sensitivity can be expected. The bioactivity
peaks for leupeptin were relatively narrow, and no extensive
dose-dependent peak broadening was observed. However, for
aprotinin, a high-aﬃnity plasmin inhibitor, extensive peak
broadening was already observed at 30 μM, due to the
sigmoidal dose−response relationship typical for bioactivity
detection.10,43 Peak broadening in postcolumn bioassaying,
such as high resolution screening43,44 and nanofractionation
analytics,4,6,7,34 seems exaggerated compared to parallel UV or
MS signals since bioassay responses are sigmoidal concen-
tration−response in nature in contrary to chemical detector
responses. Peak broadening is expected to be better visible
after nanoLC separations than after normal bore LC
separations because the column dimensions of the nanoLC
result faster in column overloading and sample preconcentra-
tion at the start of the gradient resulting in higher
concentrations of compounds when eluting.
The lowest concentration of aprotinin at which plasmin
inhibition was still observed was an injected concentration of
44 nM. The retention time of the chromatographic peak and
the bioactive peak was stable for both compounds at each
concentration measured, demonstrating robustness of the
method.
An important characteristic of the picofractionation system
is the capability to maintain the chromatographic resolution
obtained during separation. To test the picofractionation
system for this characteristic, two leupeptin diastereoisomers
were analyzed.45 Both diastereoisomers possess potent
inhibitory activities toward plasmin and can be separated by
RPLC. Previous analyses, however, were performed using a
relatively fast gradient, which did not result in diastereoisomers
separation (Figure 3). By applying a more shallow (60 min)
gradient, the leupeptin diastereoisomers were separated with
baseline resolution, allowing fractionation and microarray
bioactivity testing of the individual diastereoisomers (Figure
4). When comparing picofractionation bioassay chromato-
grams with those given in the nanofractionation study of
Zietek et al.,38 the picofractionation results do not give a better
resolution. Improvement in separation resolution of venom
proteins, however, was not the goal of the current study.
Instead, the main goal of this study was to build and
demonstrate an analytical methodology capable of postcolumn
bioassaying complex bioactive mixtures using nanoliter range
sample volumes. This oﬀers the possibility to work with
samples only available in low volumes such as snake venoms
and insect venoms. As Figure 4 shows that the diaster-
eoisomers of leupeptin can be separated and bioassayed
without loss in separation eﬃciency from the nanoLC, higher
resolutions in the system have to be achieved in the separation
component of the system and not the picofractionation aspect.
Improving the resolution of venom protein separations,
however, is not the focus of this study.
NanoLC-Microarray Bioassay Analysis of Snake
Venoms. Venoms are complex mixtures containing multiple
bioactive compounds with high potency and/or selectivity for a
range of biological targets. Hence, bioactives derived from
venoms are considered valuable entry points for drug
discovery. Although attractive for these reasons, studying
venoms can be challenging due to their complexity and, often,
minute quantities of available material.46 To evaluate the
usefulness of the nanoLC platform when coupled to both
postcolumn microarray bioassaying and MS detection, we
analyzed four venoms originating from the pit vipers Bothrops
asper, Deinagkistrodon acutus, Trimeresurus trigonocephalus, and
Trimeresurus purpureomaculatus, respectively. Figures 5 and S7
show MBCs of the four venoms correlated to UV chromato-
grams and separately obtained nanoLC-MS data. In the MBC
of B. asper, also known as fer-de-lance (Figure 5), a broad
positive signal between 28 and 33 min was observed, which
suggests that the venom contains peptides and/or proteins
with ﬁbrinolytic activity. B. asper venom is known to contain a
number of proteolytic enzymes, including class PI, PII, and
PIII snake venom metalloproteinases (SVMPs), which are at
least in part responsible for the devastating toxic eﬀects in
cases of snakebite envenoming.47 For further information on
SVMP classiﬁcation the reader is referred to a review on
SVMPs by Takeda et al.48 Other reported literature on
metalloproteinases isolated from B. asper describes hemor-
rhagic activity of SVMPs including the PI SVMP BaP1 (22.7
kDa)49 and PIII SVMP BaH4 (69 kDa).50 Considering the
width of the positive MBC peak observed, most probably the
observed bioactivity is due to multiple, partly coeluting,
bioactive compounds present in the venom. Similar broad
bioactive peaks were also observed during analyses of snake
venom samples using the normal-bore chromatography based
Figure 4. Analysis of a mixture of leupeptin diastereoisomers (25 μM)
using the picofractionation platform (top). The microarray bioassay
chromatogram (MBC) was correlated with the UV absorbance trace
(middle) and MS chromatogram (bottom). For MS analysis,
leupeptin at a concentration of 2 μM was used. BPC: base peak
chromatogram. For this analysis a long chromatographic gradient of
60 min was used.
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nanofractionation system.4 This implies that the picofractio-
nation approach provides comparable separation eﬃciency.
Upon correlating the MBC with the obtained MS data, the m/
z values of a number of component ions were observed in the
time frame of the positive MCB peak (Table S1). In Figure 5,
the total ion chromatogram (TIC) and extracted ion
chromatograms (XICs) of the relevant m/z values are plotted.
Although a number of compounds with masses in the range of
20−30 kDa were observed, and which could be SVMPs or
SVSPs (especially those eluting between 31 and 32 min), due
to the coelution of these compounds it was not possible to
determine which ion(s) were responsible for the bioactivity.
Due to the very complex composition and high diversity of
toxins in most venoms, a single separation usually does not
suﬃce in obtaining baseline separation of the venom toxins.
We have identiﬁed this limitation also in our previous studies
in which the nanofractionation platform of high-resolution
screening analytics was used. In order to address this
limitation, an orthogonal separation using two diﬀerent
separation mechanisms (e.g., RP and HILIC) can be applied
and was in fact demonstrated by us and others.6,7,38 Similar
approaches are anticipated to be applied to the picofractiona-
tion platform, however, at later stages of its development.
The venom of D. acutus, also known as “the hundred pacer”,
exhibited similar ﬁbrinolytic-like activities to those observed
for B. asper. When analyzed using the picofractionation
platform, a positive peak in the MBC between 23 and 28
min was visible (Figure S7). In addition, between 28 and 32
min, a negative peak representing plasmin inhibition was
observed. While previous reports have described ﬁbrinolytic
metalloproteinases, e.g. FIIa (26 kDa) and Dacin (23 kDa) in
the venom of D. acutus,51,52 to our knowledge antiﬁbrinolytic
activities have not yet been reported. The XICs of m/z values
detected for components eluting between 28 and 32 min are
shown in Figure S7 and originate from both singly and
multiple charged species potentially representing peptides as
well as SVMPs (∼20−30 kDa).
The other two snake venoms analyzed in this study were
from the congeneric species T. trigonocephalus and T.
purpureomaculatus, known as the Sri Lanka Pit Viper and the
Mangrove Pit Viper, respectively. The MBCs of these two
venoms showed similar proﬁles, both exhibiting ﬁbrinolytic-
like and antiﬁbrinolytic activities (Figures 5 and S7). Venom
from T. purpureomaculatus has been reported to contain a
number of proteolytic enzymes, including for example, the
thrombin-like enzyme (an SVSP) purpurase (35 kDa)53 and a
proteolytic SVMP called hemorrhagin (72 kDa).54 Our
nanoLC-MS setup was not able to eﬀectively detect such
high molecular masses due to a limited sensitivity for the
higher mass proteases that are present at low concentration.
The m/z values that were observed for the bioactivity peaks are
listed in Table S1. The negative bioactivity peak observed in
Figure 5. Analysis of venoms of B. asper (left) and T. trigonocephalus (right) using the picofractionation platform employing proﬁling of plasmin
inhibition and protease activity. B. asper shows a positive peak between retention time 28 and 33 min, indicating the presence of multiple venom
proteases and/or plasmin activators. From the parallel obtained MS data, multiple masses are found to match the positive peak area of the
microarray bioassay chromatogram (MBC) as shown as extracted-ion chromatograms (XICs). For T. trigonocephalus, both positive and negative
peaks were observed indicating the presence of proteases and/or plasmin activators as well as plasmin inhibitors. The XICs indicate multiple
potential bioactive peptides or proteins per peak.
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the MBC of T. purpureomaculatus between 29 and 33 min
(Figure S7) represents antiplasmin (antiﬁbrinolytic) activities.
In the case of T. trigonocephalus venom (Figure 5), to our
knowledge, the biochemical antiplasmin proﬁle has not been
reported yet, which can be due to the fact that the venom of
this species is considered to be of low medical relevance55 in
contrast to, for example, the venom of B. asper. Nevertheless,
clinical features of envenomation by T. trigonocephalus have
been reported to include coagulopathy and local hemor-
rhage,55 pathologies consistent with the bioactivities observed
here and which are likely due to the action of proteolytic
enzymes.
■ CONCLUSIONS
This study describes the development and application of a new
picofractionation system which couples nanoLC to microarray
bioassaying via noncontact spotting of nanoliter-range eﬄuent
fractions. A number of adaptations, such as spot-on-spot
dispensing, hydrophobic coating of deposition capillary, and
use of spot-adjacent oil droplets, allowed the eﬀective transfer
of a conventional microtiter well-plate-based bioassay to
microarray format. Suitable bioassay performance was
indicated by a good correlation of determined IC50 values
for leupeptin and aprotinin obtained with a conventional
bioassay format and with the new miniaturized method. The
new method was evaluated by the analysis of diﬀerent
concentrations of the plasmin inhibitors leupeptin and
aprotinin by the nanoLC-microarray bioassay system. The
ability of the system to achieve high-resolution fractionation at
nanoLC ﬂow rates was shown by separating and distinctively
depositing diastereoisomers of leupeptin followed by individ-
ually assessing their inhibiting activity. Furthermore, we
validated the “real-world” applicability of the picofractionation
system by screening minute amounts of snake venoms from
Bothrops asper, Deinagkistrodon acutus, Trimeresurus trigonoce-
phalus and Trimeresurus purpureomaculatus. The results
indicated the presence of proteases as well as compounds
with both antiﬁbrinolytic and ﬁbrinolytic-like properties. It
should be noted, however, that some venom toxins can
(partly) denaturate during LC separation rendering them
inactive and thus not detectable in the plasmin bioassay. In
general, the results obtained were in agreement with the
available literature. The new method described herein will
facilitate bioactivity proﬁling complex bioactive mixtures and
consumes only very low sample volumes (i.e., in the range of
50 nL to 1 μL). Anticipated future developments of the
picofractionation platform include further optimization of the
chromatographic part of the system to achieve better
separations for venoms, miniaturization of the microarray
dimensions to allow bioassay multiplexing, and implementa-
tion of an eﬄuent split after UV detection that will permit
simultaneous parallel online MS analysis next to microarray
spotting and bioassaying. The method presented in this study
is anticipated to be generic in nature in the sense that other
bioassay formats can be implemented in a straightforward
manner. Preliminary data has for example shown that a
ﬂuorescence enhancement ligand binding assay functions in
the methodology as well (data not shown). With minor
modiﬁcations (such as eﬄuent droplet ejections with MALDI
matrix solution instead of the now used water) the current
methodology is expected to be adaptable for integrated
postcolumn MALDI-MS analysis as well.
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